Loading
A phase 1/2 trial of Ruxolitinib and Fedratinib in myeloproliferative neoplasms, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) is a phase 1/2 interventional study registered as NCT04817007 by Bristol-Myers Squibb, with 216 participants enrolled, started 2021-03-22 and due to reach its primary completion in 2028-08-31. Interventions recorded: BMS-986158, Ruxolitinib and Fedratinib.
Shares Ruxolitinib, Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Ruxolitinib, Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Primary myelofibrosis, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag pipeline.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Small-molecule kinase inhibitors and the tag pipeline.